David Lebowitz
Stock Analyst at Citigroup
(0)
# 3900
Out of 5,218 analysts
102
Total ratings
43.55%
Success rate
-1.60%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PTC Therapeutics | Maintains: Sell | 26 32 | 46.45 | -31.11% | 3 | Dec 4, 2024 | |
Mirum Pharmaceutical... | Maintains: Strong Buy | 65 68 | 42.34 | 60.6% | 4 | Nov 13, 2024 | |
Incyte | Maintains: Strong Buy | 92 97 | 68.61 | 41.38% | 4 | Oct 30, 2024 | |
Intellia Therapeutic... | Maintains: Neutral | 25 19 | 12.89 | 47.4% | 6 | Oct 25, 2024 | |
Celldex Therapeutics | Initiates Coverage On: Buy | 70 | 25.36 | 176.03% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 13 15 | 8.22 | 82.48% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 178 207 | 130.25 | 58.93% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 44 | 13.2 | 233.33% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 65 76 | 93.28 | -18.52% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 37 | 20.8 | 77.88% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 302.46 | 26.3% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 42 46 | 27.5 | 67.27% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 31 | 35.01 | -11.45% | 1 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 60 | 36.62 | 63.84% | 11 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 66.03 | 45.39% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 1.64 | 631.71% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 245.25 | -33.13% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 12.63 | 208.79% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 13.89 | 51.19% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 27 | 0.7 | 3757.14% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 3.52 | 297.73% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | n/a | n/a | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |